303 followers
RT @FrontPharmacol: New Research: Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like…
RT @FrontPharmacol: New Research: Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like…
New Research: Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China #pharmacology https://t.co/OEBUQffzqA